Literature DB >> 21391669

Inhibitory effect of α-lipoic acid on platelet aggregation is mediated by PPARs.

Tz-Chong Chou1, Ching-Yu Shih, Ying-Tsung Chen.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) isoforms (α, β/δ, and γ are present in human platelets, and activation of PPARs inhibits platelet aggregation. α-Lipoic acid (ALA), occurring naturally in human food, has been reported to exhibit an antiplatelet activity. However, the mechanisms underlying ALA-mediated inhibition of platelet aggregation remain unknown. The aim of this study was to investigate whether the antiplatelet activity of ALA is mediated by PPARs. ALA itself significantly induced PPARα/γ activation in platelets and increased intracellular amounts of PPARα/γ by blocking PPARα/γ secretion from arachidonic acid (AA)-activated platelets. Moreover, ALA significantly inhibited AA-induced platelet aggregation, Ca(2+) mobilization, and cyclooxygenase-1 (COX-1) activity, but increased cyclic AMP production in rabbit washed platelets. Importantly, ALA also enhanced interaction of PPARα/γ with protein kinase Cα (PKCα) and COX-1 accompanied by an inhibition of PKCα activity in resting and AA-activated platelets. However, the above effects of ALA on platelets were markedly reversed by simultaneous addition of selective PPARα antagonist (GW6471) or PPARγ antagonist (GW9662). Taken together, the present study provides a novel mechanism by which ALA inhibition of platelet aggregation is mediated by PPARα/γ-dependent processes, which involve interaction with PKCα and COX-1, increase of cyclic AMP formation, and inhibition of intracellular Ca(2+) mobilization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21391669     DOI: 10.1021/jf103940u

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  8 in total

1.  Antiplatelet activity of nifedipine is mediated by inhibition of NF-κB activation caused by enhancement of PPAR-β/-γ activity.

Authors:  Ching-Yu Shih; I-Hsin Lin; James-Cheng Ding; Fu-Chi Chen; Tz-Chong Chou
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

2.  Evolving coronary stents coated with new bioactive agents.

Authors:  Yunseok Choi
Journal:  Korean Circ J       Date:  2011-05-31       Impact factor: 3.243

3.  Mauritia flexuosa Presents In Vitro and In Vivo Antiplatelet and Antithrombotic Activities.

Authors:  Eduardo Fuentes; Wilson Rodríguez-Pérez; Luis Guzmán; Marcelo Alarcón; Simón Navarrete; Oscar Forero-Doria; Iván Palomo
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-18       Impact factor: 2.629

4.  New mechanisms of antiplatelet activity of nifedipine, an L-type calcium channel blocker.

Authors:  Tz-Chong Chou
Journal:  Biomedicine (Taipei)       Date:  2014-11-18

Review 5.  Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.

Authors:  Francisco A Monsalve; Radha D Pyarasani; Fernando Delgado-Lopez; Rodrigo Moore-Carrasco
Journal:  Mediators Inflamm       Date:  2013-05-27       Impact factor: 4.711

Review 6.  Relationship between Platelet PPARs, cAMP Levels, and P-Selectin Expression: Antiplatelet Activity of Natural Products.

Authors:  Eduardo Fuentes; Iván Palomo
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-13       Impact factor: 2.629

7.  Inhibition of adenosine diphosphate-induced platelet aggregation by alpha-lipoic acid and dihydroquercetin in vitro.

Authors:  Ivan S Ivanov; Anastasia V Sidehmenova; Vera I Smol'yakova; Galina A Chernysheva; Mark B Plotnikov
Journal:  Indian J Pharmacol       Date:  2014 Jul-Aug       Impact factor: 1.200

Review 8.  Breaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticles.

Authors:  Katie L Lannan; Julie Sahler; Nina Kim; Sherry L Spinelli; Sanjay B Maggirwar; Olivier Garraud; Fabrice Cognasse; Neil Blumberg; Richard P Phipps
Journal:  Front Immunol       Date:  2015-02-13       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.